UY29645A1 - Derivados de pirido(2,3-d)pirimidina, su preparacion, su aplicacion en terapeutica - Google Patents

Derivados de pirido(2,3-d)pirimidina, su preparacion, su aplicacion en terapeutica

Info

Publication number
UY29645A1
UY29645A1 UY29645A UY29645A UY29645A1 UY 29645 A1 UY29645 A1 UY 29645A1 UY 29645 A UY29645 A UY 29645A UY 29645 A UY29645 A UY 29645A UY 29645 A1 UY29645 A1 UY 29645A1
Authority
UY
Uruguay
Prior art keywords
therapeutics
pyrimidine
derivatives
preparation
application
Prior art date
Application number
UY29645A
Other languages
English (en)
Spanish (es)
Inventor
Bourrie Bernard
Casellas Pierre
Jegham Samir
Pierre Perreaut
Muneaux Claude
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY29645A1 publication Critical patent/UY29645A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY29645A 2005-07-01 2006-06-30 Derivados de pirido(2,3-d)pirimidina, su preparacion, su aplicacion en terapeutica UY29645A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0507032A FR2887882B1 (fr) 2005-07-01 2005-07-01 Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique

Publications (1)

Publication Number Publication Date
UY29645A1 true UY29645A1 (es) 2007-01-31

Family

ID=36096420

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29645A UY29645A1 (es) 2005-07-01 2006-06-30 Derivados de pirido(2,3-d)pirimidina, su preparacion, su aplicacion en terapeutica

Country Status (40)

Country Link
US (2) US7504406B2 (enExample)
EP (2) EP2020410B1 (enExample)
JP (1) JP4472009B2 (enExample)
KR (1) KR101298344B1 (enExample)
CN (2) CN101213196B (enExample)
AR (1) AR054812A1 (enExample)
AT (1) ATE423119T1 (enExample)
AU (1) AU2006264801B2 (enExample)
BR (1) BRPI0613020A2 (enExample)
CA (1) CA2610794C (enExample)
CR (1) CR9568A (enExample)
CY (2) CY1110457T1 (enExample)
DE (1) DE602006005246D1 (enExample)
DK (2) DK2020410T3 (enExample)
DO (1) DOP2006000145A (enExample)
EA (1) EA014312B1 (enExample)
EC (1) ECSP078011A (enExample)
ES (2) ES2450067T3 (enExample)
FR (1) FR2887882B1 (enExample)
HR (2) HRP20090236T1 (enExample)
IL (1) IL187900A0 (enExample)
JO (1) JO2550B1 (enExample)
MA (1) MA29561B1 (enExample)
ME (1) ME01813B (enExample)
MX (1) MX2007016239A (enExample)
MY (1) MY143089A (enExample)
NO (1) NO20080418L (enExample)
NZ (1) NZ564072A (enExample)
PA (1) PA8684801A1 (enExample)
PE (1) PE20070139A1 (enExample)
PL (2) PL1902054T3 (enExample)
PT (2) PT2020410E (enExample)
RS (2) RS50781B (enExample)
SI (2) SI1902054T1 (enExample)
TN (1) TNSN07440A1 (enExample)
TW (1) TWI321566B (enExample)
UA (1) UA92021C2 (enExample)
UY (1) UY29645A1 (enExample)
WO (1) WO2007003765A1 (enExample)
ZA (1) ZA200711032B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2344484B1 (en) * 2008-10-17 2016-06-08 Akaal Pharma Pty Ltd S1p receptors modulators and use thereof
WO2010042998A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
CN103204825B (zh) * 2012-01-17 2015-03-04 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
EP2638911A1 (en) 2012-03-14 2013-09-18 Sanofi Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia
CN103833771A (zh) * 2012-11-22 2014-06-04 天津滨江药物研发有限公司 作为蛋白激酶Mek抑制剂的苯并五元杂环化合物及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
JPH04128276A (ja) 1990-09-19 1992-04-28 Pfizer Pharmaceut Co Ltd アミノベンゾサルタム誘導体およびその用途
AU711426B2 (en) * 1994-11-14 1999-10-14 Warner-Lambert Company 6-aryl pyrido(2,3-d)pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
PA8510701A1 (es) * 2000-01-25 2002-12-11 Warner Lambert Co PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
KR20020075805A (ko) * 2000-03-06 2002-10-05 워너-램버트 캄파니 5-알킬피리도[2,3-ｄ]피리미딘 타이로신 카이나제 억제제
MXPA02011263A (es) 2000-08-04 2003-03-10 Warner Lambert Co 2-(4-piridil)amino-6-dialcoxifenil- pirido(2,3-d) pirimidin-7-onas.
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
AU2002952453A0 (en) * 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US8338435B2 (en) * 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections

Also Published As

Publication number Publication date
TNSN07440A1 (en) 2009-03-17
DK1902054T3 (da) 2009-06-15
ES2450067T3 (es) 2014-03-21
JP2008544975A (ja) 2008-12-11
EP2020410B1 (fr) 2013-12-18
PL2020410T3 (pl) 2014-05-30
EP1902054A1 (fr) 2008-03-26
NZ564072A (en) 2012-02-24
EA200800223A1 (ru) 2008-06-30
ATE423119T1 (de) 2009-03-15
EP2020410A1 (fr) 2009-02-04
RS50781B (sr) 2010-08-31
MX2007016239A (es) 2008-03-06
PT1902054E (pt) 2009-04-22
SI2020410T1 (sl) 2014-04-30
CN102260258B (zh) 2015-01-07
JO2550B1 (en) 2010-09-05
IL187900A0 (en) 2008-03-20
HRP20140246T1 (hr) 2014-06-20
KR20080021714A (ko) 2008-03-07
PL1902054T3 (pl) 2009-07-31
AU2006264801B2 (en) 2012-05-10
WO2007003765A1 (fr) 2007-01-11
BRPI0613020A2 (pt) 2010-12-14
PA8684801A1 (es) 2007-01-17
CA2610794A1 (fr) 2007-01-11
NO20080418L (no) 2008-03-28
AR054812A1 (es) 2007-07-18
JP4472009B2 (ja) 2010-06-02
ECSP078011A (es) 2008-01-23
HK1122797A1 (en) 2009-05-29
US20090163522A1 (en) 2009-06-25
DOP2006000145A (es) 2008-01-31
AU2006264801A1 (en) 2007-01-11
PT2020410E (pt) 2014-03-20
KR101298344B1 (ko) 2013-08-20
DK2020410T3 (en) 2014-03-24
CR9568A (es) 2008-02-20
ZA200711032B (en) 2009-04-29
DE602006005246D1 (de) 2009-04-02
FR2887882A1 (fr) 2007-01-05
CY1114989T1 (el) 2016-12-14
US20080176874A1 (en) 2008-07-24
EP1902054B1 (fr) 2009-02-18
MA29561B1 (fr) 2008-06-02
CN101213196B (zh) 2011-09-07
US7504406B2 (en) 2009-03-17
CN101213196A (zh) 2008-07-02
TWI321566B (en) 2010-03-11
CA2610794C (fr) 2012-02-21
MY143089A (en) 2011-03-15
ES2322101T3 (es) 2009-06-16
PE20070139A1 (es) 2007-03-07
HRP20090236T1 (hr) 2009-05-31
SI1902054T1 (sl) 2009-06-30
FR2887882B1 (fr) 2007-09-07
EA014312B1 (ru) 2010-10-29
TW200745102A (en) 2007-12-16
CY1110457T1 (el) 2015-04-29
RS53211B (sr) 2014-08-29
UA92021C2 (ru) 2010-09-27
ME01813B (me) 2014-09-20
US8008310B2 (en) 2011-08-30
CN102260258A (zh) 2011-11-30

Similar Documents

Publication Publication Date Title
ECSP078011A (es) DERIVADOS DE PIRIDO[2,3-d]PIRIMIDINA, SU PREPARACION, SU APLICACION EN TERAPEUTICA
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
CY1120257T1 (el) ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΜΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ JANUS
ECSP11010904A (es) Compuestos de pirrolo[2,3-d]pirimidina
ECSP12011855A (es) COMPUESTOS DE pIrrolo[2,3-d]pIrimidinA
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
BRPI0923786C1 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
ECSP088425A (es) INHIBIDORES DE LA ACTIVIDAD Akt
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
EA201100303A1 (ru) Производные пиразоло[5,1-b]оксазола в качестве антагонистов cfr1
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.
UY29439A1 (es) Nuevos compuestos
ZA200803420B (en) Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases
CL2011000832A1 (es) Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
ATE512968T1 (de) 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6- carboxamid und 2,3,4,5-tetrahydropyrrolo(1,2-a)- diazepin-7-carboxamid- derivate, ihre herstellung und therapeutische verwendung
AR056279A1 (es) Derivados de aril 1,4- pirazina sustituidos, composicion farmaceutica y un metodo in vitro
CL2008001908A1 (es) Proceso para la preparación de 17alfa-(3-hidroxipropil)-17beta-hidroxiesteroides, los compuestos intermediarios usados en el proceso; y el proceso de preparación de dichos compuestos intermediarios.
UY29756A1 (es) Derivados de 5-piridazinil-1-azabiciclo(3.2.1) octano, su preparación y su aplicación en terapéutica.